OncLive TV

Meghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Valisha Shah, MS, discusses the observed association between clonal hematopoiesis and RCC with cardiovascular diseases.

VK Gadi, MD, PhD, discusses the challenge of identifying patients with HER2-low disease, emphasizing communication between pathologists and medical oncologists in the diagnostic process.

Talha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Eunice Wang, MD, discusses ongoing research with menin inhibitors in patients with acute leukemias, as presented at the 2024 EHA Congress.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.